Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced ...
In intensive care units, some patients who appear unconscious occupy a gray zone in their relationship to the world. To ...
Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
Imagine you’re at a bustling dinner party filled with laughter, music, and clinking silverware. You’re trying to follow a ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...
In 2026, contextual memory will no longer be a novel technique; it will become table stakes for many operational agentic AI deployments. At the beginning of the modern generative AI era, purpose-built ...
Delayed onset of canonical babbling and first words is often reported in infants later diagnosed with autism spectrum disorder (ASD). Identifying the neural mechanisms underlying language acquisition ...
Remarkably, human brains have the ability to accurately perceive and process the real-world size of objects, despite vast differences in distance and perspective. While previous studies have delved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback